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Abstract: Poly(methyl methacrylate) (PMMA) is widely used in joint arthroplasty to secure an
implant to the host bone. Complications including fracture, bone loss and infection might cause
failure of total knee arthroplasty (TKA), resulting in the need for revision total knee arthroplasty
(rTKA). The goals of this paper are: (1) to identify the most common complications, outside of sepsis,
arising from the application of PMMA following rTKA, (2) to discuss the current applications and
drawbacks of employing PMMA in managing bone loss, (3) to review the role of PMMA in addressing
bone infection following complications in rTKA. Papers published between 1970 to 2018 have been
considered through searching in Springer, Google Scholar, IEEE Xplore, Engineering village, PubMed
and weblinks. This review considers the use of PMMA as both a bone void filler and as a spacer
material in two-stage revision. To manage bone loss, PMMA is widely used to fill peripheral bone
defects whose depth is less than 5 mm and covers less than 50% of the bone surface. Treatment of bone
infections with PMMA is mainly for two-stage rTKA where antibiotic-loaded PMMA is inserted as a
spacer. This review also shows that using antibiotic-loaded PMMA might cause complications such
as toxicity to surrounding tissue, incomplete antibiotic agent release from the PMMA, roughness and
bacterial colonization on the surface of PMMA. Although PMMA is the only commercial bone cement
used in rTKA, there are concerns associated with using PMMA following rTKA. More research and
clinical studies are needed to address these complications.
Keywords: PMMA; revision total knee arthroplasty; bone loss; infection; antibiotic-loaded
bone cement
1. Introduction
Failure of total knee arthroplasty (TKA) necessitates revision total knee arthroplasty (rTKA) to
improve the function of the knee and to relieve patient pain [1,2]. The goal of rTKA is to address
complications such as bone loss and bone infection after a failed TKA. According to a recent report by
J. Funct. Biomater. 2020, 11, 25; doi:10.3390/jfb11020025 www.mdpi.com/journal/jfb
J. Funct. Biomater. 2020, 11, 25 2 of 18
the Canadian Institute for Health Information (CIHI), 84,770 (35,945, excluding patella) rTKA surgeries
were performed between 2012 and 2017 in Canada [3]; the main indications for these rTKA were
infection (38.4%), instability (22.7%) and aseptic loosening (16.5%) [3]. This correlates with a United
States (U.S.) study performed by Sharkey et al. [4], which investigated the causes of TKA failure by
performing a systematic retrospective review on 781 rTKA surgeries between 1 July 2003 and 1 July
2012 (Figure 1). Patients were divided into two groups: early (range, 1 day to 1.97 years) and late
(range, 2.01 years to 30.36 years) failure depending upon the time interval between first TKA and
subsequent rTKA. Infection was found to be the main reason for rTKA in the early failure group and
the average time interval between TKA failure and rTKA was 0.84 years. However, aseptic loosening
was the most common reason for rTKA in the late failure group, where the average time before rTKA
was 6.9 years [4].
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Among the different rTKA techniques and treatments for bone loss (augmentation, metaphyseal
sleeves, morselized allograft, and cementation [5,6]), PMMA cement is used when the bone defect
is small (less than 5 mm depth) [7–9]. In an attempt to address infection, antibiotics can be added
to PMMA [10–15]. In this review, papers published between 1970 and 2018 were consi r d, and
identified through searching in Springer, Googl Scholar, IEEE Xplore, Eng neering village, PubMed
and web links based o the topics: failure at the PMMA-bone interface, bone loss management and
antibiotic-impregnated spacers in rTKA. To our knowledge, this is the first review which focuses
on complications of using PMMA in addressing both bone loss and bone infection following rTKA.
The aim of this review was to critique the existing literature to address the following questions:
1. What are the most common complications, ou side of sepsis, regarding the use of PMMA in rTKA?
2. What are the current applications and challenges using PMMA to manage bone loss in rTKA?
3. How is PMMA used to address infection in first stage rTKA and what are the
subsequent complications?
2. PMMA
There are many papers reviewing the chemistry, utility and clinical success of PMMA in TKA.
Therefore, only a short introduction explaining the chemistry of PMMA is included.
Chemistry of PMMA
PMMA was first applied in orthopedics in 1958 for total hip arthroplasty (THA) applications [10,16,17].
Nowadays, it is the most commonly used bone cement in both TKA and rTKA. PMMA is made of powder
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and liquid components; the powder usually consists of an initiator (di-benzoyl peroxide, BPO), copolymer
beads, a radio-opacifier (BaSO4 or ZrO2) and sometimes antibiotics, whereas the liquid component consists
of the monomer (Methyl methacrylate, MMA), a stabilizer and an activator (dimethyl-para-toluidine,
DMPT) [18]. PMMA acts as a “grout” as it locks the bone and implant together mechanically, with
no chemical bonding [18]. Polymerization of PMMA starts by mixing the initiator and monomer [19],
an exothermic reaction which can be broken down into three steps [20–22]: Initiation, Propagation,
and Termination:
Initiation: a chemical reaction begins by the initiator degrading, resulting in the bond cleavage or
electron transfer and producing two fragments with unpaired electrons called free radicals.
Propagation: activated free radicals react with the monomer to form a new free radical.
The reaction of the newly formed radicals continues until there are no more monomers or a termination
reaction occurs.
Termination: there are two types of termination. One is the deletion of the monomer. The other is
a combination of two active polymer chain ends or a combination of one active polymer chain end
with an initiator radical or inhibitors [17,19].
3. Complications after rTKA
Most rTKA failures occur in the first two years following surgery [23]. Infection, aseptic loosening,
and instability are categorized as the three main causes for failure following rTKA surgery [24–27].
Although infection is the principal cause of complication after rTKA, periprosthetic fracture, extensor
mechanism insufficiency and stiffness increase the risk of further surgical intervention [28]. Most of
the complications with PMMA, which occur in primary TKA (e.g., heat generation and volumetric
shrinkage) also occur in rTKA. However, the bone stock in rTKA is often insufficient to support the
hardware components using only PMMA, and other techniques such as stemmed implants, bone
grafting or augments might be required to manage severe bone loss [29–31]. Some of the complications
(outside of sepsis) which often lead to subsequent rTKA or failure of the bond between the bone-cement
or component-bone interface in rTKA are discussed below.
3.1. Aseptic Loosening
Aseptic loosening occurs due to a failure of the bond between the bone and tibial or femoral
component in the absence of infection. It can also occur when there is insufficient initial implant
fixation due to weak mechanical integration between the PMMA and cancellous bone, bone resorption,
damage to the bone from the heat generated during PMMA polymerization [32,33] and biological
or mechanical loss of fixation over time [34]. Moreover, fragmentation of PMMA can lead to aseptic
loosening at the interface. This process can also provoke a biological response and lead to osteolysis,
the pathological destruction or disappearance of bone tissue [35,36].
3.2. Third-Body Wear
Third-body wear occurs when hard particles (such as PMMA, metal or bone) are entrapped between
the femoral component and the polyethylene bearing surface [37]. Although generation of ultra-high
molecular weight polyethylene (UHMWPE) particles are known to intensify osteolysis, PMMA cement
particles, lead to accelerated wear and subsequent osteolysis as well [37–41]. Bitar et al. [38] mentioned
that the biological response of wear particles were dependent on both the particle and host characteristics
such as size, composition and concentration. The PMMA mantle can be degraded macroscopically due to a
number of factors such as microfracture within the bulk of the PMMA mantle over time, or the movement
of bone and PMMA on the articulating surfaces [39,40]. These particles may or may not be phagocytosed
depending on the particle size. Niki et al. [41] reported the diameters of PMMA particles generated
intraoperatively to be in the range of 250–340 µm. These particles are likely to induce a three-body wear
mechanism, inducing abrasion at articulating surfaces, rather than inflammatory reactions [41]. On the
other hand, small particles (≤10 µm) might inhibit osteoblastic differentiation [42].
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3.3. Heat Generation
Exothermic polymerization of PMMA can cause bone necrosis, which results in early loosening of
the implant [43–45]. Free radicals released after polymerization can separate the covalent C=C bonds
and produce 1.4 to 1.7 × 108 J/m3 of energy in the PMMA [46]. Fukushima et al. [47] investigated
heat conduction from PMMA by using a finite element method (FEM). First, the PMMA temperature
was recorded during ten surgeries using a digital thermometer. The thickness of the PMMA layers
was also measured from x-rays and was reported as 2.8 ± 0.6 mm. The initial temperature was
measured as 32 ◦C and heat conduction was analyzed using the FEM. The maximum temperature was
predicted as 65 ◦C at the PMMA and 56 ◦C at the bone-PMMA interface. As thermo-necrosis of bone
occurs at temperatures above 53 ◦C [45], results indicated that the high temperature produced during
polymerization might lead to bone necrosis and loosening of implanted joint prostheses. Moreover,
it also indicated that the thickness of the PMMA layer affects necrosis, i.e., the thinner the PMMA,
the less the necrosis [47].
3.4. Volumetric Shrinkage
Volumetric shrinkage is mostly due to polymerization [48]. During the process, the liquid monomer
is converted to a solid polymer and the associated change in density is considered the primary cause of
shrinkage [49]. The overall theoretical volume shrinkage is estimated to be up to 7% [50–52]. Lennon
et al. [53] proposed a physical model containing a medial and lateral layer of PMMA between the bone
and component surface to understand the damage accumulation around PMMA. The residual stress
was approximately 4–7 MPa caused by shrinkage which could increase to more than 24 MPa due to
local stress concentration caused by the presence of pores and/or if interdigitation raised the stress at the
bone-PMMA interface. It was concluded that this residual stress was influenced by the temperature. Orr
et al. [48] injected Palacos R® (Heareaus Medical, Germany) into ring molds (60 mm × 60 mm × 3 mm).
They measured the polymerization temperature and analyzed the circumferential stress of PMMA rings
caused by shrinkage. The circumferential stress increased by increasing the temperature. Calculated
circumferential stress of curing PMMA was in the range of 8.4–25.2 MPa for setting temperatures of
60–140 ◦C. The circumferential stress at 80 ◦C was 12.6 MPa, which was reported as the ultimate stress of
PMMA [48]. Moreover, the ratio of monomer to polymer and the ambient polymerization conditions
were crucial in controlling the pre-load cracking [53].
4. Management of Bone Defects in rTKA
For successful surgical outcomes, it is crucial to manage bone deficiencies in rTKA which require
proper pre-operative evaluation and surgical planning [5]. Not only does bone deficiency restrain
component alignment, but it also prevents rTKA stabilisation [7]. To categorize femoral and tibial
defects in rTKA, several classifications and protocols have been introduced [7,8]. These classifications
are defined so that surgeons accurately evaluate bone loss and decide which approach leads to the best
treatment based on the location, size, and severity of defect in rTKA [54]. Each classification targets
different aspects (appearance, size or severity) and might consider the tibia, femur or both bones [6,55].
The most frequently used classification of bone defects in rTKA is the Anderson Orthopedic Research
Institute (AORI) one [6], which considers description and treatment options for bone defects in the
femur and tibia separately, (Table 1) [7,56]. Below are the characteristics of the AORI classification [8,57]:
1. The terminology used for femoral and tibial defects is the same because the metaphyseal segment
of both femur and tibia are similar;
2. As there is no cortical bone in the metaphyseal segment of the proximal tibia and distal
femur, the common definitions which were used in most classifications (cortical /cancellous,
contained/uncontained, central/peripheral) were eliminated;
3. The definitions in AORI are precise. This reduces the ambiguity when characterizing the
bone defect;
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4. The number of defect types in this classification is minimal to allow researchers to have sufficient
cases for statistical analysis;
5. The classification provides intraoperative and postoperative radiographic data, therefore;
researchers would have access to the retrospective categorization of cases.
Table 1. Description, characteristics and treatment options of bone deficiencies in rTKA by Anderson
Orthopedic Research Institute (AORI) classification [56].
Type Description Characteristics Treatment Option





Defects in one femoral condyle or one
tibial plateau












Deficient metaphyseal segment; a
bone loss that comprises a major





In AORI, each femoral and tibial bone defect is categorized into three types and for each, a specific
treatment is suggested [6]. The following should be observed in preoperative assessment of femoral (F) or
tibial (T) bone to be categorized in any of F1/T1, F2/T2, F2a/T2a, F2b/T2b and F3/T3 type of defect (Figure 2).
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4.1. Management of F1/T1 Defect
The literature since 1984 has reported limitations in the use of PMMA for managing large bone
defects [6–8,54,59]. Recent reports show that this limitation still exists [9,60–62]. PMMA is mainly
used to fill peripheral bone efects having a depth of less than 5 mm and covering less tha 50% of the
bone surface [6,60–65]. In the case of deficiencies with 5–10 mm depth, screws can be implemented
with PMMA [61]. If the component position is misaligned, screws can be used in combination with
PMMA to maintain the proper stability of the component during the polymerization of PMMA [59,61].
Ritter et al. [66] examined the use of PMMA with screws for tibial defects (9 mm height) in 59 patients
for a mean follow-up of 2–3 years and reported that in 27% of cases, radiolucency up to 1 mm in the
bone-PMMA interface was observed. Therefore, it was concluded that screws should be used along
with PMMA to fill bone defects greater than 5 mm [66].
4.2. Management of F2/T2 Defect
4.2.1. Management of F2A
If the bone defect in one condyle is 5–10 mm deep, techniques such as morselized allografts
or metal augments can be used [7,8,60]. Management of F2A defect is crucial since resection of the
opposite condyle more than the proximal level, can convert F2A defect to F2B. The damaged condyle
must be fixed by using a technique such as modular augmentation in order to restore the normal joint
line [6].
4.2.2. Management of F2B
Augmentation might be performed for both femoral condyles (distally and posteriorly) to restore
the joint line [67]. Another option is using PMMA to replace the lost femoral condyle [5]. In some
F2B defects, elevation of the joint line is necessary to provide motion and prevent further stiffness,
so stemmed components have been recommended (with or without augmentation) [56].
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Management of T2A
To manage T2A, a stemmed implant has been suggested as a management option in this defect.
The stem might be inserted in the tibial portion to decrease the movement of the implant [68]. A small
autograft, allograft or wedged tibial component would help in fixation of the implant when there is
insufficient bone [69]. PMMA can also be attached to the undersurface of the tibial tray to increase
fixation with an augment [70].
Management of T2B
Porous tantalum (Ta) tibial cones can be used in the treatment of type-2 and type-3 defects to
restore the proximal tibia metaphysis [30]. When two plateaus are involved, the surgical options are a
long-stemmed tibial component, a bone graft, augmentation or PMMA reinforced with screws in order
to reconstruct the tibial plateau [6].
Stems
Stems are used to decrease strain at the bone-cement interface (distal femur or proximal tibia) by
transferring the load to a larger area in order to provide additional mechanical stability for component
fixation [71]. Stems can be cemented or cementless (press-fit) [72,73]. Table 2 shows a comparison of
cemented and cementless stem techniques in rTKA with a minimum 24-month follow-up.
Table 2. Comparison of cemented and cementless stems in rTKA.
Author Year of Study Number ofrTKA Remarks
Winemaker et al. [74] 1996–2003 17 cemented15 cementless
Better early stability of cemented stems
Short-term radiographic results were not
affected by cementing technique
Barrack et al. [75] Notmentioned
66 cemented
50 cementless
Higher localized pain at the end of the
cementless stem (14%) in comparison with
cemented stem (11%)
Fehring et al. [76] 1986–2003 107 cemented95 press-fit
Modified Knee Society radiographic scoring
system used
Higher stability rate for the cemented stem
(93%) in comparison with cementless (71%)
Edwards et al. [73] 1990–2010 102 cemented126 cementless
Lower rate of radiographic failure for
cementless stem.
Similar reinfection rate in both stems.
Kosse et al. [77] 2008–2010 12 cemented11 cementless
No difference in clinical outcome and
micro-motion for both cemented and
cementless stems
Fleischman et al. [78] 2003–2013 108 cemented316 cementless
Similar risk of mechanical failure for both
cemented and cementless stems
Higher risk of failure for patients <65 years
when cemented stem is used
As seen in Table 2; over time, cementless stems showed similar survivorship, and reinfection
and mechanical failure rates to cemented stems. From 2008, no significant differences in failure rates
were observed between cemented and cementless stems. Cementless stems are usually longer than
cemented stems and press-fitted to the diaphysis of the bone, whereas cemented stems are fixed at the
metaphysis of the bone [79]. There are concerns regarding the use of both cemented and cementless
stems. One complication of short cemented stems is that they are unable to reach the diaphysis of the
bone and therefore, in cases of severe bone loss, using short-cemented stems may result in component
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misalignment. Additionally, removing these stems in the future would increase the chance of bone
loss [80].
4.3. Management of F3/T3 Defect
4.3.1. Management of F3 Defect
Reconstruction in this type of defect is more complicated than the other types due to severe
bone loss. Most often, this defect occurs as a result of movement of the stem along the axis of the
femur. PMMA is not suggested to be used here due to the wide defect area [81]. Shrinkage of
PMMA, inadequate penetration, lack of biodegradability and bioactivity, thermal necrosis and poor
osteointegration restrict the use of PMMA in an F3 defect [82]. Management includes the use of
structural allograft, cones or metaphyseal sleeves [8].
4.3.2. Management of T3 Defect
A major portion of the proximal tibia must be replaced with a large allograft or custom-made
component [67].
5. Management of Infection in rTKA
One of the main challenges after TKA is the risk of infection [83–85]. rTKA due to infection is
$60,000 more expensive than revision due to the increased risk of aseptic loosening and mechanical
failure [86]. In order to eradicate the infection, the patient has to stay longer in the hospital and multiple
surgeries are often needed [87]. Currently, there are three options for treating infection in rTKA:
(1) Debridement, antibiotics and implant retention (DAIR) (2) single-stage rTKA and (3) two-stage
rTKA [88]. Discussing DAIR is out of the scope of this review paper. Therefore, two procedures
(single-stage and two-stage rTKA) are discussed below.
5.1. Single-Stage rTKA
The first single-stage rTKAs were performed in 1976 (Hamburg, Germany) on 104 infected
knees [89]. In single-stage rTKA, the infected tissue and implant are removed, along with any PMMA;
remnants of the PMMA may cause severe joint pain and aseptic loosening [90,91]. Following this,
rTKA is performed.
5.2. Two-Stage rTKA
Two-stage revision is the most commonly used method for treating infection in rTKA and involves
two separate steps. In the first step, the infected implant and pre-implanted PMMA should be
removed with debridement of infected bone and soft tissue. The resulting gap is then filled with an
antibiotic-containing PMMA spacer [92], which releases a high concentration of antibiotics locally to
treat the infection [83]. After 6–8 weeks, the PMMA spacer is removed and TKA is performed.
5.3. Comparison between Single-Stage and Two-Stage rTKA
There is a debate about the effectiveness of single-stage or two-stage rTKA in eradicating infection.
Table 3 presents some of the literature’s conclusions on the outcomes of using either single-stage or
two-stage rTKA.
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Table 3. Comparison between single-stage and two-stage for treatment of infection in rTKA.
Author Number ofStudies Reviewed
Number of Single-stage
and Two-stage rTKA Outcome
Masters et al. [93] 63 studies
58 studies two-stage
4 studies single-stage
1 study mix of two rTKA
Not enough evidence to support a
technique
Chew et al. [94] 12 studies(433 revision) Not mentioned
Lack of evidence to address if
single-stage is thorough enough to
treat deep infection
Baker et al. [95] 122 cases 33 single-stage162 two-stage
No statistical differences on knee
function between single-stage and
two-stage rTKA,
Nagra et al. [88] 796 studies 46 single-stage185 two-stage
No significant differences in the risk
of reinfection after single-stage rTKA
Kunutsor et al. [96] 118 studies 10 single-stage108 two-stage
Single-stage revision strategy is as
effective as the two-stage revision
among unselected patients in general
From Table 3, it can be concluded that there is still controversy about whether single-stage rTKA
is a better technique for patients. Lack of consistency with regards to sample size, limited number of
single-stage rTKAs, period of antibiotic therapy and lack of detailed subgroup analysis are some of
the limitations, which prevent a robust comparison of the effectiveness in single-stage and two-stage
techniques [88,96,97]. Yan et al. mentioned two-stage rTKA as the most preferable technique in North
America [97]. The Canadian Joint Replacement Registry (CJRR) reported different reasons for knee
revision among 2468 procedures performed between 2016 and 2017 (Table 4).
Table 4. Reasons for rTKA among single-stage and two-stage rTKA (2016–2017) [3].
Reason for rTKA Number of Failed Procedures
Infection: single-stage rTKA 288
Infection: stage one of two-stage rTKA 216
Infection: stage two of two-stage rTKA 268
Total 2468
Table 4 shows that the total failed rTKA due to infection in two-stage rTKA (stage one and two)
was higher than that of the single-stage procedure. However, no details of the causes for such infections
were provided in the report. Nagra et al. [88] recommended two-stage rTKA over single-stage for
patients with sepsis, the presence of infection with no organism recognition, difficult pre-operative
culture treatment, the appearance of sinus tract and deficient non-viable soft tissue.
5.4. Antibiotic-Loaded PMMA
In the case of infection, high dose antibiotic-loaded PMMA can be used in rTKA [15]. Antibiotics
in the spacer should target both gram-negative and gram-positive pathogens. Thermal stability, low
risk of allergy, maintaining low influence on the mechanical properties of PMMA and low binding
with protein are other desired properties of antibiotic bone cement [98]. Two types of antibiotic-loaded
PMMA spacers used in two-stage revision after chronically infected TKA are static (non-articulating)
and dynamic (articulating) spacers [98,99].
5.4.1. Static-PMMA Based Spacer
Static-PMMA spacers are made of one block of antibiotic-loaded PMMA fitted into the joint space
for the purpose of releasing antibiotic drugs into the surrounding area [100–102]. When using a static
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spacer, the knee joint can only be in full extension or minimal flexion [98]. One significant drawback of
the static spacer is that they lock the joint by creating a temporary arthrodesis, restricting range of
motion (ROM) between the stages of revision [98,102]. It is also reported that static spacers increase
bone loss [103,104] as the patient is unable to move the knee. This is explained by Wolff’s law; decreased
loading on the bone results in a reduced bone density due to a decrease in the stimulus necessary for
bone remodeling [105,106]. Other disadvantages include joint stiffness after rTKA, instability, wound
healing problems and capsular and quadricep scarring [107]. These factors drove the development of
dynamic-PMMA spacers [107].
5.4.2. Static Versus Dynamic Spacers
Hsu et al. [108] compared the range of motion in static and dynamic spacers. ROM in maximum
flexion before the first-stage rTKA was different for static and dynamic spacers (ROM for static
spacer = 0◦; ROM for dynamic spacer= 4◦; P < 0.001); a two-year follow-up also showed differences
in ROM for both groups (ROM for static spacer = 78◦; ROM for dynamic spacer = 95◦, p = 0.019)
meaning that the dynamic spacer facilitated ROM more significantly than that of the static spacer.
No significant difference in reinfection rate was reported for static and dynamic spacers [109,110].
However, care should be taken in using dynamic spacers in type F3 bone defect [111].
5.4.3. Dynamic-PMMA Based Spacer
Dynamic spacers have shown similar eradication rates to static spacers in treating the chronic
prosthetic joint infection (PJI) in rTKA while facilitating joint mobility during recovery. Several
studies reported dynamic spacers improve ROM and decrease bone loss [110,112]. Two categories
of intraoperatively-made dynamic spacers are cement-on-cement and metal-on-polyethylene
(PROSTALAC) spacers [112].
Cement-on-Cement Dynamic Spacers
Cement-on-cement spacers can be either molded or pre-fabricated [98]. Molds have various sizes
and shapes and can be fabricated with PMMA and a provisional component which is the same size
as the original implant [112]. After filling the mold with the antibiotic-loaded PMMA, the mold is
removed and the spacer substituted for the old prosthesis [112,113]. A pre-fabricated dynamic spacer
is another form of cement-on-cement dynamic spacer which is made in different sizes and loaded with
antibiotics [114]. The use of a pre-fabricated spacer is more economical than the molded spacers and
reduces operative time [115].
Metal-on-Polyethylene Spacer (PROSTALAC™)
The PROSTALAC™ system consists of a metal-on-polyethylene articular surface and
antibiotic-loaded PMMA (DePuy, Warsaw, IN, USA [116,117]. These can be created with commercially
available mold or a homemade mold fabricated by the surgeon [118]. Gooding et al. [119] compared
115 two-stage revisions using the PROSTALAC system. The interval between two surgeries was
approximately 17 weeks [119]. Following the second-stage revision, each patient was examined, first
after 3 months and again at 6 months, 1 year and then yearly up to 5 to 12 years. The results showed
that the use of PROSTALAC spacers led to the prevention of re-infection in 98% of cases [119].
5.4.4. Concerns Regarding Use of Antibiotic-Impregnated PMMA Spacers
Several studies have reviewed both articulating and non-articulating PMMA spacers [98,111,120–122].
The delivery of thermosensitive antibiotics is not possible with PMMA due to the heat generated
during curing of PMMA [43]. Moreover, PMMA is a non-resorbable material which must be removed
in the second stage of rTKA [123]. Microorganisms tend to adhere to tissue surface and implanted
biomaterials by encasing themselves in biofilm made of polysaccharide and protein [124,125]. PMMA
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is in direct contact with bone and blood, so plasma protein forms the conditioning film on the surface
of PMMA. The initial burst release of antibiotic from PMMA occurs within 24 h, with poorly sustained
elution [126,127]. If the concentration of antibiotic passes a sub-inhibitory level, the immune system
might consider the PMMA as a foreign body and risk of secondary infection would increase [128].
Once the burst is over, PMMA can act as a bed for bacterial colonization (178). The incomplete drug
release of PMMA might be related to the hydrophobic nature of PMMA (although carbonyl groups of
PMMA create a small bond with water) [129].
Roughness is another important factor which affects the adherence of bacteria on the surface
of PMMA [130]. Dantas et al. [131] concluded that an increase in PMMA roughness facilitated
bacterial adhesion due to the presence of grooves and pits and protection of bacteria from shear forces.
Roughness plays an important role in early plaque formation. Roughened surfaces offer a greater area
for bacterial colonization [132]. Taylor et al. showed that a low roughness (Ra = 1.24 µm) increases the
bacterial adhesion significantly [132]. The area covered by P. aeruginosa increased up to 18% when the
surface of PMMA was abraded (Ra = 1.24 µm), while on a smooth surface (Ra = 0.04 µm) the area of
bacterial attachment reduced to 12% [132]. Therefore, the characteristics of the surface of PMMA is
crucial to avoiding bacterial resistance in the future [133].
6. Conclusions
PMMA is predominantly used to solve two peri-operative issues in rTKA: bone loss and bone
infection. This review attempted to address three main objectives regarding employing PMMA in
rTKA. The following conclusions were made:
1. Regarding the most common complications, outside of sepsis, involving the use of PMMA in
rTKA. Most literature reported infection as the major cause of failure in rTKA [96,98,119]. Using
PMMA also resulted in wear debris, bone necrosis and volumetric shrinkage. These might
lead to complications such as tissue necrosis, instability of the implant, increased bone loss and
subsequent loosening;
2. Investigating the current applications and drawbacks of using PMMA in addressing bone loss in
rTKA. Literature since 1984 has mentioned limitations in using PMMA for large defects and recent
reports showed no deviation on this issue [6,8,54,59–62,64]. According to the AORI classification,
PMMA alone can only be used in F1/T1 defects having a depth of less than 5 mm and covering less
than 50% of the bone surface [9,60–63]. We conclude that drawbacks such as crack propagation
and loosening [18] restrict the use of PMMA in large bone defects.
3. Reviewing how PMMA is used to address bone infection in rTKA and what subsequent
complications might result; PMMA is the standard for delivering antibiotics in infected rTKA.
Antibiotic PMMA spacers are used as a treatment for patients with late chronic infection in
two-stage rTKA. Although dynamic-PMMA spacers facilitate some ROM, care should be taken in
using them in type-F3 bone defects. Moreover, the optimal procedure for infection eradication
(single or two-stage rTKA) is still controversial in the literature [88,93–96]. Therefore, further
research for guidance on single-stage vs. two-stage rTKA in managing infection is warranted.
Our review demonstrated that issues such as the initial burst of antibiotic release from PMMA,
with poor subsequent sustained elution, bacterial colonization on the surface of the PMMA,
roughness, heat generation during polymerization and lack of porosity influence the long-term
effect of PMMA-loaded antibiotics.
In conclusion, although PMMA is the only commercial bone cement used for rTKA, there are
some issues of concern and therefore room for improvement. Further investigation is warranted to
address complications following the use of PMMA in rTKA.
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